SMAD3 and neoplasm: It was suggested that the inhibition of Smad3 in tumor MO-MDSC was markedly reversed by mutating the m6A site at position 4591, but not 3037 (Fig. 6M), which was restored by administration of STM2457 (Fig. 6N).